J&J's PALMAZ-SCHATZ STENT SHOWS CONTINUED RESTENOSIS REDUCTION
This article was originally published in The Gray Sheet
Executive Summary
J&J's PALMAZ-SCHATZ STENT SHOWS CONTINUED RESTENOSIS REDUCTION compared to balloon angioplasty in one-year follow-up results from the Stent Restenosis (STRESS) study. Of the 205 patients randomized for treatment via Johnson & Johnson Interventional Systems' Palmaz-Schatz stent implantation, 10.2% required target lesion revascularization (coronary artery bypass surgery or repeat angioplasty) within one year. This figure compared to an 18.4% rate in the 202-patient group receiving percutaneous transluminal coronary angioplasty. The STRESS researchers said that the continued trend of fewer events in the stent group is "concordant with the reduced restenosis rates" associated with stenting.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.